OR-GUROBI-OPTIMIZATION
Gurobi Optimization, LLC , creator of the world’s fastest mathematical optimization solver, announced the launch of their new educational game that aims to show players the power of optimization. The “Burrito Optimization Game” is a free, web-based app designed for data science and operations research students, as well as anyone who stands to benefit from mathematical optimization. In addition to demonstrating the value of optimization, the game also proves its difficulty, as well as the importance of algorithms and solvers in finding an optimal solution.
Gurobi created the Burrito Optimization Game in collaboration with Dr. Larry Snyder of Lehigh University, who explains that at the time he and Gurobi started work on the project, there were several other projects in the data science community that used the premise of locating a hypothetical new restaurant. The projects scored possible locations based on demographics, demand, and other data science factors.
“As optimizers, we know it can be easy to pick the single best location once you have a score, but if you need to pick five, ten, or fifty locations, especially when there are thousands to choose from, that becomes a very different kind of problem,” says Dr. Snyder. “So we decided to use this as a way to introduce the optimization story, hoping that the idea of first coming up with a score for each location and then putting that into an optimization context would resonate, even for data scientists who hadn’t seen the restaurant examples.”
Gurobi’s game is based on a classic facility location problem and allows players to choose the best locations for a “Guroble” food truck, with the goal of maximizing their total profit. For each level, players are presented with a new story, with added complexity, and a set of data to help them make decisions. The data provided typically includes the cost of each truck, the price of ingredients, and the total sales revenue for each burrito sold, as well as scenarios that will impact decision-making—such as disruptions in the burrito ingredient supply chain, or weather conditions that impact a customer’s willingness to travel.
Players can drag and drop their Guroble trucks around an illustrated map, where they can see how many customers are in each building. The closer the truck is to a building, the more customers from that building will be willing to walk to the truck to buy a burrito. Players can see how their profits adjust when they drag and drop the truck to a different location, highlighting the importance of trade-offs in complex decision-making.
Once a player is satisfied with their placement of the trucks, Gurobi will solve the problem and find the optimal solution within a fraction of a second. Players can then see how far they were from the optimal solution in terms of total profit.
The game also provides tips along the way to further the learning experience once players submit their solution. For example, players might be notified that a certain part of the city is underserved, or they’ll see a hint that their solution has the optimal number of trucks, but in the wrong locations.
In subsequent rounds, the game introduces uncertainties for an added challenge. Players need to build their solutions based off of forecasts rather than actual demand in this game—a concept that’s very familiar for data science students. For example, there might be 25 potential customers forecast in a building, but the actual amount could be off by up to five customers. Error bars indicate how far in either direction the actual demands might be.
“What we’re hoping to convey is that if you were to try optimization by trial and error, it’s not only tedious and time-consuming, but it’s also hard to make good decisions,” explains Dr. Snyder. “We also wanted to make clear that although optimization is hard, it’s a mature scientific field with robust commercial and open-source software that can solve these problems for us.”
“We launched this a little while ago, and the early feedback has been extremely positive,” explained Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization. “One common response from optimization professionals is excitement about the prospect of having a simple, entertaining way to show the people they work with the sorts of problems optimization can solve and the power that it brings.”
The Burrito Optimization Game is available on Gurobi’s website , accompanied by a series of resources that highlight intended educational takeaways and explain how instructors can teach the game in a classroom setting or how players can use the game on their own.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver—the Gurobi Optimizer—which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support—so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
